AG-120 for Chondrosarcoma

Recruiting in Palo Alto (17 mi)

+6 other locations

Overseen by Ciara Kelly, MBBCh BAO

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Prior Safety Data

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.

Research Team

Ciara Kelly, MBBCh BAO

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for adults with advanced or recurrent chondrosarcoma and an IDH1 gene mutation. Participants must have stable vital organ functions, no severe infections, not be pregnant or breastfeeding, agree to use two forms of contraception if they can reproduce, and not have used certain other treatments recently.

Inclusion Criteria

I can take pills by mouth.

You are expected to live for at least four more months.

I am not pregnant or have confirmed contraception use if capable of becoming pregnant.

Exclusion Criteria

My heart's pumping ability is below 40% as shown by recent tests.

I haven't had radiotherapy or local treatment for cancer spread in the last 2 weeks.

I have previously been treated with an IDH1 inhibitor.

Treatment Details

Interventions

• AG-120 (IDH1 Inhibitor)

Trial Overview The study tests AG-120's effectiveness and safety in treating chondrosarcoma with the IDH1 mutation. It examines how well patients respond to this oral medication when their cancer has returned or spread despite previous treatment.

Participant Groups

Group I: Chondrosarcoma Experimental Treatment 1 Intervention

Participants will have locally advanced/metastatic or recurrent operable chondrosarcoma

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

Lisa M. DeAngelis

Memorial Sloan Kettering Cancer Center

Chief Medical Officer since 2021

MD from Columbia University

Selwyn M. Vickers

Memorial Sloan Kettering Cancer Center

Chief Executive Officer since 2022

MD from Johns Hopkins University

Agios Pharmaceuticals, Inc.

Industry Sponsor

Trials

55

Recruited

4,200+